These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27680105)

  • 1. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
    Soini E; Hallinen T; Brignone M; Campbell R; Diamand F; Cure S; Aalto-Setälä M; Danchenko N; Koponen H; Kolasa K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
    Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.
    Young AH; Evitt L; Brignone M; Diamand F; Atsou K; Campbell R; Cure S; Danchenko N
    J Affect Disord; 2017 Aug; 218():291-298. PubMed ID: 28478358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
    Brignone M; Diamand F; Painchault C; Takyar S
    Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
    Lomas J; Llewellyn A; Soares M; Simmonds M; Wright K; Eastwood A; Palmer S
    Pharmacoeconomics; 2016 Sep; 34(9):901-12. PubMed ID: 27289476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
    Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
    Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
    Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
    BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression.
    Singh A; Brooks MM; Voorhees RE; Potter MA; Roberts MS; Luther JF; Wisniewski SR
    Psychiatr Serv; 2017 Jan; 68(1):81-87. PubMed ID: 27524365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
    J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
    Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
    J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Hatano M; Matsuda Y; Iwata N
    Mol Psychiatry; 2023 Jan; 28(1):402-409. PubMed ID: 36253442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
    van Baardewijk M; Vis PM; Einarson TR
    Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
    Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
    Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
    Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
    [No Abstract]   [Full Text] [Related]  

  • 19. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
    CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.